The University of Kansas BRAIN Lab is conducting a research study to learn about behavioral and brain differences associated with premutations of the Fragile X gene, FMR1.
Participation
Who can participate?
Individuals ages 50–80 with the FMR1 gene premutation with or without FXTAS may be eligible to participate. Individuals with no known diagnosis may also be eligible to participate as a control subject.
What will happen in the study?
If the individual qualifies and decides to be in this research study, they will come to the University of Kansas – Lawrence and the University of Kansas Medical Center for 3–4 visits over the course of a few months subject to participants availability.
The following is a list of some of the tasks that will happen during the study:
- Cognitive
- Clinical
- Fine motor
- Eye movement
- Posture and gait
- Functional MRI testing
What are the good things that can happen from this research?
The goal of this study is to gain a better understanding of the cognitive and motor issues associated with FXTAS and identify markers associated with FXTAS onset.
What are the bad things that can happen from this research?
The potential risks related to testing are minimal, and they are no greater than those experienced through regular clinical evaluations. There may be other risks that we do not know about yet.
Will you/your child be paid to complete this survey?
Participants receive $10 per hour of testing completed, up to $140. Travel reimbursement is not currently available for participants.
Study Doctor
Dr. Matthew Mosconi, PhD
Associate Professor at University of Kansas – Lawrence
Director of Kansas Center for Autism Research and Training
Our Most Recent Opportunities
Conference Research Opportunity: Validation of Fragile X-Associated Tremor Ataxia Syndrome Rating Scale (FXTAS-RS)
Rush University is conducting a research study to validate a rating scale created to assess the motor symptoms of people with FXTAS – the “Fragile X-Associated Tremor Ataxia Syndrome Rating Scale (FXTAS-RS)”
Study: Connection between Cognition and Genetic Factors in Adults with FXS
Drs. Craig Erickson and Lauren Schmitt at Cincinnati Children’s Hospital are conducting a series of research studies to learn about the brain and cognition and how they are connected with genetic factors related to FXS.
Study: UNC Brain Development Research Study of Infants with Fragile X Syndrome
UNC Chapel Hill is conducting a research study to learn about the early brain and behavioral development of infants with FXS to aid in the future development of better supports and treatments.
Conference Research Opportunity: Cincinnati Research & Treatment Center Biorepository
Researchers at Cincinnati Children’s Hospital Medical Center want to partner with you or your child to learn more about Fragile X. The Cincinnati Research & Treatment Center team will be conducting research in San Diego at the Town and Country Resort from July 12-14th, 2022 for International Fragile X Meeting attendees. All ages are welcome to participate.
BRIDGE Study: Brain Indicators of Development Growth
A longitudinal research study from The Wilkinson Lab at the Boston Children’s Hospital Labs of Cognitive Neuroscience to learn about how differences in brain activity affect learning, language, and behavior in Fragile X Syndrome.
Clinical Trial RECONNECT: ZYN002 Gel
This study will evaluate the efficacy and safety of ZYN002, a clear cannabidiol (CBD) gel that can be applied to the skin (called transdermal application) twice a day for the treatment of behavioral symptoms of Fragile X syndrome (FXS).